OS Therapies Inc. Files S-1/A for IPO
Ticker: OSTX · Form: S-1/A · Filed: Jun 7, 2024 · CIK: 1795091
| Field | Detail |
|---|---|
| Company | Os Therapies Inc (OSTX) |
| Form Type | S-1/A |
| Filed Date | Jun 7, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $4.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: ipo, pharmaceutical, sec-filing
TL;DR
OS Therapies IPO filing updated. Looks like they're serious about going public.
AI Summary
OS Therapies Inc. filed an S-1/A amendment on June 7, 2024, for its initial public offering under registration number 333-279839. The company, incorporated in Delaware with its principal executive offices in Rockville, Maryland, is in the Pharmaceutical Preparations industry. Paul A. Romness serves as the President and Chief Executive Officer.
Why It Matters
This filing indicates OS Therapies Inc. is moving forward with its public offering, which could provide capital for its pharmaceutical development and expansion efforts.
Risk Assessment
Risk Level: medium — As an S-1/A filing, it pertains to an initial public offering, which inherently carries risks associated with new market entrants and unproven business models.
Key Numbers
- 333-279839 — SEC File Number (Identifies the specific registration statement for OS Therapies Inc.)
- 2834 — SIC Code (Indicates the company operates in the Pharmaceutical Preparations industry.)
Key Players & Entities
- OS Therapies Inc. (company) — Registrant
- 333-279839 (dollar_amount) — SEC File Number
- June 7, 2024 (date) — Filing Date
- Paul A. Romness (person) — President and Chief Executive Officer
- Rockville, Maryland (location) — Principal Executive Offices
FAQ
What is the purpose of this S-1/A filing?
This is an amendment to the Form S-1 registration statement, indicating updates or revisions to the initial filing for OS Therapies Inc.'s proposed initial public offering.
When was this amendment filed?
The amendment was filed on June 7, 2024.
Who is the President and CEO of OS Therapies Inc.?
Paul A. Romness, MPH, is the President and Chief Executive Officer of OS Therapies Incorporated.
Where are OS Therapies Inc.'s principal executive offices located?
The principal executive offices are located at 15825 Shady Grove Road, Suite 135, Rockville, Maryland 20850.
What is the company's primary industry classification?
The company's primary Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,606 words · 18 min read · ~15 pages · Grade level 14.4 · Accepted 2024-06-07 15:51:22
Key Financial Figures
- $4.00 — ssumed initial public offering price is $4.00 per share. We have applied to list our
Filing Documents
- ea0205761-06.htm (S-1/A) — 5922KB
- ea020576106ex3-2_ostherap.htm (EX-3.2) — 14KB
- tos_logo.jpg (GRAPHIC) — 83KB
- timage_001.jpg (GRAPHIC) — 324KB
- timage_002.jpg (GRAPHIC) — 333KB
- tflowchart_001.jpg (GRAPHIC) — 317KB
- 0001213900-24-050739.txt ( ) — 17619KB
- osti-20240331.xsd (EX-101.SCH) — 71KB
- osti-20240331_cal.xml (EX-101.CAL) — 26KB
- osti-20240331_def.xml (EX-101.DEF) — 308KB
- osti-20240331_lab.xml (EX-101.LAB) — 460KB
- osti-20240331_pre.xml (EX-101.PRE) — 313KB
- ea0205761-06_htm.xml (XML) — 2840KB
RISK FACTORS
RISK FACTORS 14 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 50
USE OF PROCEEDS
USE OF PROCEEDS 51 DIVIDEND POLICY 53 CAPITALIZATION 54
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 57
BUSINESS
BUSINESS 69 MANAGEMENT 87
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 94
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 98 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 99
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK 101 SHARES ELIGIBLE FOR FUTURE SALE 106
UNDERWRITING
UNDERWRITING 108 LEGAL MATTERS 112 EXPERTS 112 WHERE YOU CAN FIND MORE INFORMATION 112 INDEX TO FINANCIAL STATEMENTS F-1 i Table of Contents ABOUT THIS PROSPECTUS We have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus or any applicable prospectus supplement. You should assume that the information appearing in this prospectus or any prospectus supplement is accurate only as of the date on the front of those documents only, regardless of the time of delivery of this prospectus or any applicable prospectus supplement, or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. We are not, and the underwriters are not, offering to sell or seeking offers to purchase these securities in any jurisdiction where the offer or sale is not permitted. We and the underwriters have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities as to distribution of the prospectus outside of the United States. The industry and market data and certain other statistical information used throughout this prospectus are from our own research, surveys or studies conducted by third parties and indu